[1] |
Ling C, Cao S, Kong X. Changes of FSTL1 and MMP-9 levels in patients with acute cerebral infarction and its relationship with hemorrhagic transformation[J]. J Clin Neurosci, 2022, 99: 164-168. DOI: 10.1016/j.jocn.2021.10.041.
|
[2] |
Li Y, Lin Y, Shi Z, et al. Safflower yellow pigment and Sanqi Panax notoginseng in the treatment of acute cerebral infarction: a systematic review, meta-analysis, and cost-effectiveness analysis[J]. Ann Transl Med, 2021, 9(18): 1407. DOI: 10.21037/atm-21-782.
|
[3] |
|
[4] |
|
[5] |
|
[6] |
Chalos V, van der Ende NAM, Lingsma HF, et al. National institutes of health stroke scale: an alternative primary outcome measure for trials of acute treatment for ischemic stroke[J]. Stroke, 2020, 51(1): 282-290. DOI: 10.1161/STROKEAHA.119.026791.
|
[7] |
Rangaraju S, Haussen D, Nogueira RG, et al. Comparison of 3-month stroke disability and quality of life across modified rankin scale categories[J]. Interv Neurol, 2017, 6(1-2): 36-41. DOI: 10.1159/000452634.
|
[8] |
|
[9] |
|
[10] |
|
[11] |
|
[12] |
Zhang H, Han S, Zhang L, et al. Recombinant plasminogen activator modified nanoparticles for targeting thrombolysis in branch retinal vein occlusion[J]. Cell Mol Biol (Noisy-le-grand), 2022, 68(3): 201-212. DOI: 10.14715/cmb/2022.68.3.23.
|
[13] |
|
[14] |
|
[15] |
|